Neuroendocrine tumors usually arise in the gastrointestinal tract (50%) or bronchopulmonary 30% [1]. The liver is a usual site for neuroendocrine metastasis. Upon diagnosis, it is important to differentiate between a primary and metastatic tumor. Primary neuroendocrine tumors of the liver are usually an incidental finding, without the characteristic carcinoid syndrome, Patient may present unspecific symptoms such as abdominal pain or discomfort, abdominal distention, or less frequently jaundice [1, 2]. Although there is no specific classification for primary NET of the liver, to determine tumor aggressiveness, WHO classifies NET as G1 G2, or G3, depending on the proliferation index or Ki67. Recurrence and survival at 5 years are 18% and 78% respectively. Given that most hepatic neuroendocrine carcinomas usually are metastasis from other organs, the diagnosis of a primary neuroendocrine tumor is based on the exclusion of the disease in every other location. Radiological findings are similar in primary and metastasic NET, bronchopulmonary, and gastrointestinal tract should be explored to exclude extrahepatic disease [1].

For resectable tumors, surgery is the treatment of choice, either wedge resection or partial hepatectomy, with a 5-year survival rate of approximately 70%. In non-resectable tumors, therapy can vary from arterial embolization, somatostatin analog therapy, systemic 5flouracyl, and liver transplantation. Tumors of higher histological grade, Ki 67 and poorly differentiated have a worse prognosis [1, 3].